The Clinical Research Of The Prophylaxis Of Recombinant Human Erythropoietin On Bronchopulmonary Dysplasia Of Preterm Infants

Objective To evaluate the prophylax of recombinant human erythropoietin(rhuEPO)on bronchopulmonary dysplasia of preterm infants.Methods We randomly assigned 155 infants who were born at 26-to-29-weeks'gestation to rhuEPO-treated group(n=78) or control group(n=77) as soon as they were hospitalized. Randomization was stratified according to gestational age (26 or 27weeks and 28 or 29weeks). RhuEPO-treated group was given the rhuEPO of the dosage of 100IU /kg/ time, but NS for the control group. RhuEPO was injected subcutaneous for each other day with 3 times each week for a duration of 4 weeks. The supportive care was same among the groups.We assessed outcomes at 36 weeks'gestational age:(1)The death of the infant;(2)The rate of the bronchopulmonary dysplasia and the grade of the bronchopulmonary dysplasia;(3)Oberserve complications of the infant about pneumonia,sepsis,necrotizing enterocolitis(NEC),intraventricular hemorrhage (IVH),patent ductus arteriosus(PDA),retinopathy of prematurity(ROP);(4)Evaluate the safety of the rhu-EPO about hypertension and erythrocytosis.Result1,At 36 weeks'gestational age,9 infants were excluded(6 infants had died)in the contol group;19 infants were excluded(10 infants had died)in the rhuEPO-treated group.There was no difference between two groups about the rate of the death(P>0.05). 2,The significant difference of the rate of bronchopulmonary dysplasia which was lower in rhuEPO treated group(P<0.05).3,The significant difference of the time of the mechanical ventilation and oxygeon therapy which was lower in rhuEPO treated group(P<0.05).4,compared with control group. The incidence of complication of two groups: there was no difference between them in the incidence of pneumonia,sepsis,necrotizing enterocolitis(NEC),intraventricular hemorrhage (IVH),patent ductus arteriosus(PDA),retinopathy of prematurity(P>0.05).5,Evaluate the safety of the rhuEPO: there was no difference between two groups in the incidence of hypertention and erythrocytosis(P>0.05).Conclusion1,There was no serious side effect with rhuEPO treatment.2,RhuEPO treatment can reduce the time of the mechanical ventilation and oxygeon therapy.3,RhuEPO treatment on preterm infants could reduce the rate of bronchopulmonary dysplasia .